Financial News

Zivo Bioscience, Inc. Announces Pricing of Upsized $13.8 Million Public Offering and Up-listing to Nasdaq

Products You May Like

KEEGO HARBOR, Mich., Might 27, 2021 (GLOBE NEWSWIRE) — Zivo Bioscience, Inc. (OTCMKTS:ZIVO) a biotech/agtech R&D firm engaged within the improvement and commercialization of dietary/nutraceutical product candidates initially derived from proprietary algal cultures, right this moment introduced the pricing of its upsized underwritten public providing of two,760,000 items at a worth to the general public of $5.00 per unit. Every unit to be issued within the providing consists of 1 share of frequent inventory and one warrant to buy one share of frequent inventory at an train worth of $5.50. The frequent inventory and warrants are instantly separable and shall be issued individually. The frequent inventory and warrants are anticipated to start buying and selling on the Nasdaq Capital Market, on Might 28, 2021, underneath the symbols “ZIVO” and “ZIVOW,” respectively. ZIVO expects to obtain gross proceeds of $13.8 million, earlier than deducting underwriting reductions and commissions and different estimated providing bills. In reference to the providing, the Firm will effectuate a reverse cut up of its issued and excellent frequent inventory at a ratio of 1-for-80. The reverse inventory cut up is predicted to be efficient at 12:01 a.m., Jap Time, on Might 28, 2021. The share numbers and pricing data on this launch are adjusted to provide impact to the reverse inventory cut up.

ZIVO has granted the underwriters a 45-day choice to buy as much as an extra 414,000 shares of frequent inventory and/or an extra 414,000 warrants on the public providing worth to cowl over-allotments, if any. The providing is predicted to shut on June 2, 2021, topic to customary closing situations.

Maxim Group LLC is performing as lead ebook working supervisor, and Joseph Gunnar & Co., LLC is performing as co-book working supervisor for the providing.

The providing is being performed pursuant to the Firm’s registration assertion on Type S-1 (File No. 333-251221), as amended, beforehand filed with and subsequently declared efficient by the Securities and Trade Fee (“SEC”). A remaining prospectus regarding the providing shall be filed with the SEC and shall be accessible on the SEC’s web site at Digital copies of the ultimate prospectus regarding this providing, when accessible, could also be obtained from Maxim Group LLC, 405 Lexington Avenue, 2nd Ground, New York, NY 10174, at (212) 895-3745. 

This press launch shall not represent a proposal to promote or the solicitation of a proposal to purchase these securities, nor shall there be any sale of those securities in any state or jurisdiction during which such supply, solicitation or sale could be illegal previous to registration or qualification underneath the securities legal guidelines of any such state or jurisdiction.

About Zivo Bioscience, Inc.

Zivo Bioscience, Inc. (OTCQB:ZIVO) is a Michigan-based biotech/agtech firm engaged within the investigation of the well being and dietary advantages of bioactive compounds derived from its proprietary algal cultures, and the event of pure bioactive compounds to be used as dietary dietary supplements and meals components, in addition to biologically derived and artificial candidates for medicinal and pharmaceutical functions in people and animals, particularly centered on the final advantages of autoimmune and inflammatory response modulation.

Ahead Trying Statements

Apart from any historic data, the issues mentioned on this press launch include forward-looking statements throughout the that means of Part 27A of the Securities Act of 1933 and Part 21E of the Securities Trade Act of 1934. Ahead–wanting statements embrace, amongst others, statements concerning the Firm’s anticipated closing of the underwritten public providing. Though ZIVO believes that we’ve got an inexpensive foundation for every forward-looking assertion, we warning you that these statements are primarily based on a mixture of details and components at the moment recognized by us and our expectations of the long run, about which we can’t be sure. Our precise future outcomes could also be materially totally different from what we anticipate resulting from components largely exterior our management, together with dangers that the providing could not shut on time or in any respect, dangers that our strategic partnerships could not facilitate the commercialization or market acceptance of our merchandise; dangers that our merchandise will not be prepared for commercialization in a well timed method or in any respect; dangers that our merchandise is not going to carry out as anticipated primarily based on outcomes of our pre-clinical and medical trials; our means to lift further funds; uncertainties inherent within the improvement technique of our merchandise; adjustments in regulatory necessities or selections of regulatory authorities; the scale and progress potential of the markets for our merchandise; the outcomes of medical trials, our means to guard our mental property rights and different dangers, uncertainties and assumptions, together with these described underneath the heading “Threat Components” in our filings with the Securities and Trade Fee. These ahead–wanting statements communicate solely as of the date of this press launch and ZIVO undertakes no obligation to revise or replace any ahead–wanting statements for any purpose, even when new data turns into accessible sooner or later.

Investor Relations

Jules Abraham

Primary Logo

Products You May Like